AstraZeneca/Daiichi Sankyo's Enhertu Shows Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca and Daiichi Sankyo's drug ENHERTU showed strong and durable tumor responses in previously treated patients with HER2 mutant advanced lung cancer in the DESTINY-Lung02 phase 2 trial. The results were presented at the IASLC 2023 World Conference on Lung Cancer and published in the Journal of Clinical Oncology.
September 11, 2023 | 8:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's drug ENHERTU, developed in partnership with Daiichi Sankyo, showed positive results in a phase 2 trial for advanced lung cancer.
Positive clinical trial results often lead to increased investor confidence, which can drive up the stock price. Given that ENHERTU is being jointly developed with Daiichi Sankyo, this news is highly relevant to AstraZeneca.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100